All lobbying filings
DENDREON PHARMACEUTICALS, LLC
DENDREON PHARMACEUTICALS, LLC filed a Q3 report for DENDREON PHARMACEUTICALS, LLC on November 4, 2026.
Lobbying for DENDREON PHARMACEUTICALS, LLC
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Nov 4, 2026
Expenses
$59,650
What this organization spent lobbying with its own staff.
Reported using the LDA's own definitions (method A): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
2
Lobbying activity
2
Issues related to the Department of Veterans Affairs National Oncology Program's Prostate Cancer Oncology Clinical Pathway.
Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.